查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2014931

肺癌治療市場：2026年至2032年全球市場預測（依治療方法、給藥途徑、治療分期、疾病分期、處方狀態、通路、癌症類型及最終用戶分類）

Lung Cancer Therapeutics Market by Therapy Type, Mode Of Administration, Line Of Therapy, Disease Stage, Prescription Status, Distribution Channel, Cancer Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2024 年肺癌治療市場價值為 307 億美元，預計到 2025 年將成長至 332.3 億美元，複合年成長率為 8.70%，到 2032 年將達到 598.9 億美元。

主要市場統計數據
基準年 2024 307億美元
預計年份：2025年 332.3億美元
預測年份：2032年 598.9億美元
複合年成長率 (%) 8.70%

全面介紹影響肺癌治療創新和交付的科學、臨床和醫療保健系統發展趨勢。

由於持續存在的臨床需求、快速的科學進步以及不斷變化的監管和報銷環境，肺癌治療在腫瘤學領域中佔據著至關重要的地位。近年來，肺癌治療模式已從標準化的細胞毒性療法轉向以標靶治療和免疫調節療法為主的精準醫療。這一轉變得益於腫瘤分子特徵的進一步細化、伴隨診斷的廣泛應用以及更先進的臨床實驗室設計，這些都加速了治療方法的檢驗，並最佳化了患者選擇。

重新定義肺癌治療策略：分子特徵分析、免疫腫瘤聯合治療和監管適應的重大變化。

肺癌治療格局正經歷一場變革，主要得益於科學突破、法規演變和治療模式轉變的共同推動。分子腫瘤學的進步拓展了治療標靶，使其不再局限於傳統的驅動基因突變；新一代定序和液態生物檢體技術則能夠更早、更精準地檢測治療標靶生物標記。同時，免疫腫瘤學也日趨成熟，發展出複雜的聯合治療策略，旨在透過將查核點抑制劑與大規模標靶治療、抗體藥物偶聯物或新型免疫調節劑聯合應用，擴大能夠獲得持續療效的患者群體。

對 2025 年美國關稅措施將如何重塑肺癌治療的供應鏈結構、製造決策和籌資策略進行全面分析。

2025年實施的關稅措施的累積影響，為肺癌治療的整個價值鏈增添了新的複雜性，影響了生產成本、供應鏈設計和籌資策略。對原料、活性藥物成分和專用設備的關稅調整，促使贊助商和契約製造獎勵重新評估其地理佈局和供應商組合。為此，許多機構正在採取雙重採購策略，並加強與供應商的夥伴關係，以降低單一供應商依賴所帶來的風險，並確保關鍵試劑和組件的持續供應。

針對治療方法、治療階段、腫瘤類型、給藥途徑和分銷管道的詳細細分見解，將影響藥物的開發和取得。

精準掌握細分市場的發展趨勢，對於使研發和商業策略與臨床實際情況及給藥管道相契合至關重要。在分析治療方法類型時，必須考慮化療、免疫療法、放射線治療和標靶治療的不同研發管道和臨床效用。化療在某些治療方法中仍然發揮基礎性作用，其中烷化劑、含鉑類藥物類藥物、紫杉烷類藥物和拓樸異構酶抑制劑在聯合治療治療和序貫治療中各自佔據不同的應用領域。免疫療法包括CTLA-4抑制劑、PD-1抑制劑和PD-L1抑制劑等查核點抑制劑，它們的作用機制、給藥途徑和生物標記依賴性各不相同。放射線治療仍然是一種重要的局部治療方法，包括近距離放射、體外放射治療和立體定位放射線治療，每種方法的適用性取決於腫瘤部位和治療目標。分子標靶治療越來越按照分子標靶進行細分，包括 ALK 抑制劑、BRAF 抑制劑、EGFR 抑制劑和 ROS1 抑制劑，這些都需要與伴隨診斷和抗藥性管理策略相協調。

影響美洲、歐洲、中東和非洲以及亞太地區醫療監管准入、報銷和分銷策略的關鍵區域趨勢。

區域趨勢對監管時間表、報銷框架和商業性實施策略有顯著影響。在美洲，監管機構和保險公司優先考慮療效比較和基於價值的安排，導致公立和私人醫療系統之間的部署模式存在差異。儘管該地區通常在快速引入新型標靶治療和免疫療法方面發揮引領作用，但它也面臨著來自保險公司主導的利用管理和價格談判的壓力，而強力的衛生經濟學證據和患者支持計劃在這些方面至關重要。

策略競爭格局概述，重點在於整合產品組合、生物技術創新管線和合作夥伴生態系統，以加速肺癌治療的進步。

肺癌治療領域的競爭格局呈現出多元化的特點，既有大型製藥企業，也有致力於研發新治療方法的生物技術公司，還有能夠加速藥物開發和商業化的專業服務供應商。市場領導者憑藉整合了後期研發項目、豐富的研發管線和成熟的商業基礎設施的綜合產品組合脫穎而出。這些企業通常利用其與全球監管機構談判的經驗以及與支付方溝通的能力，加速產品上市，並在治療市場中佔據穩固地位。

為研發和商業化團隊制定切實可行的策略挑戰，以協調生物標記主導的研發、供應彈性以及對支付方有反應的證據產生。

產業領導企業應優先考慮一系列切實可行的舉措，以應對臨床複雜性、供應鏈中斷和支付方需求。首先，將研發項目與穩健的生物標記策略和伴隨診斷結合，能夠最佳化患者篩選，並增強對支付者和臨床醫生的價值提案。早期投資轉化研究和適應性測試設計，可以縮短研發週期，並使產品與標準療法相比更具差異化優勢。其次，透過採購多元化、區域製造夥伴關係和模組化生產技術來增強供應鏈韌性，有助於在降低關稅和中斷風險的同時，維持交貨時間。

我們透明的調查方法結合了文獻綜述、專家意見和跨部門證據整合，為可操作的結論和決策提供支援。

本分析的研究方法結合了系統性的文獻整合、專家訪談和跨領域證據檢驗，從而確保了研究結果的可靠性和可操作性。研究人員仔細審查了同儕審查的臨床數據、監管指導文件和公共衛生建議，作為臨床和監管解釋的基礎。此外，研究還納入了臨床醫生、藥物經濟學家、供應鏈專家和診斷試劑開發人員的初步定性意見，以指導有關產品引進、患者護理管道和報銷趨勢等方面的實際考慮。

摘要強調科學創新、營運韌性與實證策略與支付方之間的互動，以期對病患產生持久影響。

總之，肺癌治療正處於十字路口，科學發展勢頭必須與營運靈活性和與相關人員相符的價值驗證相結合。分子標靶治療、免疫腫瘤學和診斷技術的進步拓展了治療的可能性，但商業化的成功取決於能否將這些進步轉化為可及且永續的治療路徑。供應鏈中斷和貿易政策的變化凸顯了製定韌性計畫的重要性，而支付方也越來越要求提供全面的真實世界數據和以結果為導向的合約。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 肺癌治療市場：依治療方法

  • 化療
    • 烷化劑
    • 含鉑類藥物
    • 紫杉烷類藥物
    • 拓樸異構酶抑制劑
  • 免疫療法
    • CTLA-4抑制劑
    • PD-1抑制劑
    • PD-L1抑制劑
  • 放射線治療
    • 近距離放射治療
    • 外部輻射
    • 立體定位放射治療
  • 支持性護理
    • 止吐藥
    • 骨轉移抑制劑
    • 造血生長因子
  • 外科手術
  • 分子標靶治療
    • 間變性淋巴瘤激酶（ALK）抑制劑
    • BRAF抑制劑
    • EGFR抑制劑

第9章 肺癌治療市場：依給藥途徑分類

  • 吸入
  • 注射藥物
  • 口服

第10章 肺癌治療市場：依治療階段分類

  • 第 1 行
  • 第二行
  • 從第三行開始

第11章 肺癌治療市場：依疾病分期分類

  • 第一階段
  • 第二階段
  • 第三階段
  • 第四階段

第12章 肺癌治療市場：依處方狀態分類

  • 品牌
  • 非專利的

第13章 肺癌治療市場：依通路分類

  • 實體零售
  • 線上零售

第14章 肺癌治療市場：依癌症類型分類

  • 非小細胞肺癌（NSCLC）
    • 腺癌
    • 大細胞癌
    • 鱗狀細胞癌
  • 小細胞肺癌（SCLC）

第15章 肺癌治療市場：依最終用戶分類

  • 門診靜脈輸液治療中心
  • 癌症中心
  • 居家醫療
  • 醫院

第16章 肺癌治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第17章 肺癌治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第18章 肺癌治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第19章：美國肺癌治療市場

第20章：中國肺癌治療市場

第21章 競爭情勢

  • 2024年市場集中度分析
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2024 年
  • 2024年產品系列分析
  • 基準分析，2024 年
  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-437A5D08AE3F

The Lung Cancer Therapeutics Market was valued at USD 30.70 billion in 2024 and is projected to grow to USD 33.23 billion in 2025, with a CAGR of 8.70%, reaching USD 59.89 billion by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 30.70 billion
Estimated Year [2025] USD 33.23 billion
Forecast Year [2032] USD 59.89 billion
CAGR (%) 8.70%

Comprehensive introduction to the evolving scientific, clinical, and health system dynamics shaping lung cancer therapeutic innovation and delivery

Lung cancer therapeutics occupy a pivotal position within oncology due to persistent clinical need, rapid scientific advances, and evolving regulatory and reimbursement landscapes. Recent years have seen a shift from one-size-fits-all cytotoxic approaches toward precision medicine paradigms that harness targeted therapies and immune modulation. This transformation is underpinned by deeper molecular characterization of tumors, broader adoption of companion diagnostics, and more sophisticated clinical trial designs that accelerate therapeutic validation while refining patient selection.

Moreover, the clinical community is increasingly focused on integrating multimodal regimens that combine systemic agents with localized interventions, aiming to improve survival outcomes while preserving quality of life. Health systems and payers are adapting to long-term treatment pathways that raise new questions about value, affordability, and equitable access. Consequently, stakeholders across industry, clinical practice, and policy are re-evaluating development strategies and commercial models to align scientific promise with real-world delivery. In this context, careful synthesis of clinical evidence, regulatory signals, supply chain resilience, and stakeholder incentives becomes essential for guiding next-wave investments and market entry strategies.

High-impact shifts in molecular characterization, combination immuno-oncology approaches, and regulatory adaptation that are redefining therapeutic strategies for lung cancer

The landscape of lung cancer therapeutics is experiencing transformative shifts driven by convergence of scientific breakthroughs, regulatory evolution, and changing care paradigms. Advances in molecular oncology have expanded actionable targets beyond classical driver mutations, while next-generation sequencing and liquid biopsy technologies have enabled earlier and more accurate detection of actionable biomarkers. At the same time, immuno-oncology has matured into nuanced combination strategies that seek to convert durable responders into a larger patient cohort by pairing checkpoint inhibitors with targeted agents, antibody-drug conjugates, or novel immune modulators.

Regulatory bodies are also adapting, offering accelerated and adaptive pathways that reward clinically meaningful improvements and facilitate conditional approvals tied to real-world evidence generation. Payer frameworks are beginning to incorporate outcomes-based contracting and indication-specific pricing to manage long-term cost exposure. Operationally, pharmaceutical and biotech companies are forging deeper collaborations with diagnostic developers, contract research organizations, and specialized service providers to streamline development timelines and ensure diagnostic-drug co-deployment. As a result, competitive differentiation increasingly depends on integrated evidence packages, scalable manufacturing, and flexible commercialization strategies that account for heterogeneous patient populations and diverse care settings.

Integrated analysis of how 2025 United States tariff measures are reshaping supply chain architectures, manufacturing decisions, and procurement strategies across lung cancer therapeutics

The cumulative effects of tariff actions originating in the United States in 2025 have introduced new layers of complexity across the lung cancer therapeutics value chain, influencing production costs, supply chain design, and sourcing strategies. Tariff adjustments that apply to raw materials, active pharmaceutical ingredients, and specialized equipment have created incentives for sponsors and contract manufacturing partners to reassess geographic footprints and supplier portfolios. In response, many organizations have initiated dual-sourcing strategies and closer supplier partnerships to mitigate single-point vulnerabilities and preserve continuity of critical reagent and component flows.

Beyond direct cost implications, tariffs have accelerated conversations around onshoring and regional manufacturing capacity as a means to shorten lead times and reduce exposure to cross-border trade volatility. Such strategic moves typically require significant capital allocation and regulatory alignment, particularly when relocating sterile injectable or biologic drug production. Consequently, some developers have prioritized process intensification and modular manufacturing technologies to achieve flexibility without fully relocating operations.

Additionally, tariffs have ripple effects on ancillary services, including diagnostic test production and medical device supply chains that support therapeutic administration and monitoring. Health systems are adapting procurement practices to balance near-term budgetary pressures against long-term resilience, often negotiating longer-term contracts with manufacturers or leveraging strategic inventories for critical inputs. In aggregate, these adjustments emphasize the importance of supply chain transparency, scenario planning, and close engagement with customs and trade specialists to maintain program timelines and patient access in a shifting tariff environment.

In-depth segmentation insights across therapeutic modalities, lines of care, tumor types, administration routes, and distribution channels shaping development and access

A nuanced understanding of segment-level dynamics is essential for aligning development and commercial strategies with clinical realities and delivery channels. When therapies are analyzed by therapy type, it is important to consider the distinct developmental pathways and clinical utility of chemotherapy, immunotherapy, radiation therapy, and targeted therapy. Chemotherapy retains a foundational role in certain regimens, with alkylating agents, platinum-based compounds, taxanes, and topoisomerase inhibitors each occupying defined niches in combination and sequential approaches. Immunotherapy encompasses checkpoint blockade modalities such as CTLA-4 inhibitors, PD-1 inhibitors, and PD-L1 inhibitors, which vary in mechanism, dosing paradigms, and biomarker dependencies. Radiation therapy remains a critical local modality and includes brachytherapy, external beam radiation, and stereotactic body radiation, each offering differential applicability based on tumor location and intent of care. Targeted therapy is increasingly stratified by molecular targets, including ALK inhibitors, BRAF inhibitors, EGFR inhibitors, and ROS1 inhibitors, which demand companion diagnostic alignment and resistance-management strategies.

Line-of-therapy segmentation reveals strategic inflection points for clinical development and commercialization. Adjuvant and neoadjuvant settings require robust translational endpoints and longer-term outcome demonstration, while first-line, maintenance, second-line, and third-line-and-beyond indications demand clear differentiation on safety, durability, and sequencing compatibility. Differentiating a candidate in early lines often unlocks broader adoption but also requires head-to-head or pragmatic comparative evidence. When classifying by type of lung cancer, non-small cell lung cancer and small cell lung cancer present divergent biological behaviors and therapeutic modalities; NSCLC benefits from a rich targetable landscape and immunotherapy responsiveness, whereas SCLC requires intensified focus on systemic combinations and early detection strategies.

Mode-of-administration considerations-whether inhalation, injectable, or oral-shape patient adherence, site-of-care economics, and distribution logistics. Oral agents facilitate outpatient continuity and can reduce infusion resource burden, but raise adherence monitoring and drug-drug interaction considerations. Inhalation delivery offers localized exposure for select therapeutic modalities but depends on device compatibility and payer acceptance. Injectable therapeutics, particularly biologics and ADCs, demand infusion infrastructure and cold-chain logistics. Finally, distribution channel segmentation spanning hospital pharmacies, online pharmacies, retail pharmacies, and specialty clinics influences access pathways and reimbursement negotiation points. Each channel has unique contracting dynamics and patient support program implications, with specialty clinics often central to complex therapy administration and monitoring. Taken together, these segmentation lenses inform prioritization of clinical programs, supply strategies, and commercial engagement plans that align with clinical utility and care delivery realities.

Critical regional dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine regulatory access, reimbursement, and distribution strategies for therapeutics

Regional dynamics exert strong influence on regulatory timelines, reimbursement frameworks, and commercial execution strategies. In the Americas, regulatory authorities and payers emphasize comparative effectiveness and value-based arrangements, with heterogeneous adoption patterns across public and private systems. This region often leads in rapid adoption of novel targeted agents and immunotherapies but faces pressure from payer-driven utilization management and pricing negotiations that necessitate robust health economic evidence and patient support programs.

Across Europe, the Middle East, and Africa, regulatory pathways and reimbursement approaches vary widely. Western European markets typically demand comprehensive health technology assessments and real-world evidence, while emerging markets in the region may prioritize affordability and access programs. Regulatory harmonization efforts and cross-border clinical collaborations are increasingly important for achieving scale in drug development and post-approval evidence generation. The Middle East and Africa present both opportunity and complexity due to variable infrastructure, heterogeneous disease burden reporting, and different procurement models that require adaptive market-entry tactics.

The Asia-Pacific region represents a diverse landscape where rapid adoption can hinge on local regulatory reforms, domestic manufacturing capacity, and national cancer control priorities. Several countries in the region are accelerating approvals for targeted therapies and immunotherapies through conditional pathways tied to real-world evidence, while others maintain stringent local clinical requirements. Additionally, evolving initiatives to expand genomic testing and decentralized care delivery are reshaping patient identification and treatment uptake. Collectively, these regional nuances highlight the need for geographically tailored evidence strategies, flexible pricing arrangements, and supply-chain designs that accommodate regulatory and infrastructural diversity.

Strategic competitive overview emphasizing integrated portfolios, biotech innovation pipelines, and partner ecosystems that accelerate lung cancer therapeutic advancement

The competitive landscape in lung cancer therapeutics is characterized by a blend of large pharmaceutical companies, biotechs advancing novel modalities, and specialized service providers that enable rapid development and commercialization. Market leaders tend to differentiate through integrated portfolios that combine late-stage assets, pipeline depth, and established commercial infrastructure. These organizations often leverage global regulatory experience and payer engagement capabilities to accelerate launches and secure place-in-therapy positions.

Smaller biotechs and academic spinouts contribute disproportionate innovation, particularly in emerging modalities such as bispecific antibodies, antibody-drug conjugates, and cell-based therapies. These entities frequently pursue strategic partnerships or selective co-development agreements with larger sponsors to access development and commercial scale. Contract research and manufacturing partners play an instrumental role in enabling flexible development timelines and managing biologics complexity, while diagnostics developers are critical collaborators for companion assays and biomarker-driven clinical strategies. Across the competitive set, success increasingly depends on integrated evidence generation, adaptable commercial models, and the ability to demonstrate real-world benefit in diverse health system contexts.

Actionable strategic imperatives for developers and commercial teams to align biomarker-driven development, supply resilience, and payer-ready evidence generation

Industry leaders should prioritize a set of actionable initiatives to navigate clinical complexity, supply-chain disruption, and payer demands. First, aligning development programs with robust biomarker strategies and companion diagnostics will improve patient selection and strengthen value propositions for payers and clinicians. Investing early in translational research and adaptive trial designs can shorten development cycles and create clearer differentiation against standard-of-care comparators. Secondly, building supply-chain resilience through diversified sourcing, regional manufacturing partnerships, and modular production technologies will mitigate tariff- and disruption-related risks while preserving delivery timelines.

Third, commercial teams should design evidence-generation plans that include real-world data collection, health economic modelling, and outcomes-based contracting options to address payer concerns about long-term value. Engaging key opinion leaders and multidisciplinary treatment centers early can facilitate guideline inclusion and appropriate uptake. Fourth, optimizing patient support and adherence programs-particularly for oral and outpatient-administered therapeutics-will drive persistence and outcomes, requiring integration with digital tools and specialty pharmacy networks. Finally, companies should consider flexible pricing and access strategies that reflect regional affordability constraints and promote equitable access, leveraging tiered contracting, compassionate use frameworks, and strategic partnerships with public and non-profit stakeholders. Taken together, these actions create a pragmatic road map for translating scientific advances into sustainable clinical and commercial impact.

Transparent research methodology combining literature review, expert input, and cross-functional evidence integration to support actionable conclusions and decision-making

The research approach underpinning this analysis combines systematic literature synthesis, expert interviews, and cross-functional evidence triangulation to ensure robust and actionable insights. Peer-reviewed clinical data, regulatory guidance documents, and public health advisories were reviewed to anchor clinical and regulatory interpretations. In addition, primary qualitative inputs from clinicians, pharmacoeconomists, supply-chain specialists, and diagnostic developers informed practical considerations around implementation, patient pathways, and reimbursement dynamics.

Methodologically, the study emphasizes evidence integration across preclinical mechanistic understanding, clinical trial outcomes, and real-world practice patterns. Analytical techniques included comparative therapeutic class assessment, scenario planning for supply-chain contingencies, and qualitative valuation of commercial models. Care was taken to validate assumptions through subject matter expert workshops and to cross-check policy interpretations with publicly available regulatory communications. Limitations include the rapidly evolving nature of clinical evidence and policy environments, which the methodology addresses by recommending periodic updates and staged deep dives tied to major regulatory or clinical inflection points.

Concluding synthesis emphasizing the interplay of scientific innovation, operational resilience, and payer-aligned evidence strategies to achieve durable patient impact

In conclusion, lung cancer therapeutics stand at a juncture where scientific momentum must be matched by operational dexterity and stakeholder-aligned value demonstration. Advances in molecular targeting, immuno-oncology, and diagnostics have expanded therapeutic possibilities, yet commercialization success will hinge on the ability to translate those advances into accessible, sustainable care pathways. Supply-chain disruptions and trade policy shifts have underscored the importance of resilience planning, while payer expectations increasingly demand comprehensive real-world evidence and outcomes-focused contracting.

Looking forward, stakeholders who integrate biomarker-driven development with flexible manufacturing, region-specific access strategies, and payer-oriented evidence plans will be best positioned to convert clinical innovation into meaningful patient impact. By maintaining close collaboration across clinical, regulatory, commercial, and supply-chain disciplines, organizations can navigate complexity and accelerate the translation of promising therapies into standard-of-care options that improve outcomes for patients with lung cancer.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2024
  • 3.5. FPNV Positioning Matrix, 2024
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Lung Cancer Therapeutics Market, by Therapy Type

  • 8.1. Chemotherapy
    • 8.1.1. Alkylating Agents
    • 8.1.2. Platinum-Based
    • 8.1.3. Taxanes
    • 8.1.4. Topoisomerase Inhibitors
  • 8.2. Immunotherapy
    • 8.2.1. CTLA-4 Inhibitors
    • 8.2.2. PD-1 Inhibitors
    • 8.2.3. PD-L1 Inhibitors
  • 8.3. Radiation Therapy
    • 8.3.1. Brachytherapy
    • 8.3.2. External Beam Radiation
    • 8.3.3. Stereotactic Body Radiation
  • 8.4. Supportive Care
    • 8.4.1. Antiemetics
    • 8.4.2. Bone-Modifying Agents
    • 8.4.3. Hematopoietic Growth Factors
  • 8.5. Surgery
  • 8.6. Targeted Therapy
    • 8.6.1. Anaplastic Lymphoma Kinase (ALK) Inhibitors
    • 8.6.2. BRAF Inhibitors
    • 8.6.3. EGFR Inhibitors

9. Lung Cancer Therapeutics Market, by Mode Of Administration

  • 9.1. Inhalation
  • 9.2. Injectable
  • 9.3. Oral

10. Lung Cancer Therapeutics Market, by Line Of Therapy

  • 10.1. First-Line
  • 10.2. Second-Line
  • 10.3. Third-Line & Beyond

11. Lung Cancer Therapeutics Market, by Disease Stage

  • 11.1. Stage I
  • 11.2. Stage II
  • 11.3. Stage III
  • 11.4. Stage IV

12. Lung Cancer Therapeutics Market, by Prescription Status

  • 12.1. Branded
  • 12.2. Generic

13. Lung Cancer Therapeutics Market, by Distribution Channel

  • 13.1. Offline Retail
  • 13.2. Online Retail

14. Lung Cancer Therapeutics Market, by Cancer Type

  • 14.1. Non-Small Cell Lung Cancer (NSCLC)
    • 14.1.1. Adenocarcinoma
    • 14.1.2. Large Cell Carcinoma
    • 14.1.3. Squamous Cell Carcinoma
  • 14.2. Small Cell Lung Cancer (SCLC)

15. Lung Cancer Therapeutics Market, by End User

  • 15.1. Ambulatory Infusion Centers
  • 15.2. Cancer Centers
  • 15.3. Homecare Settings
  • 15.4. Hospitals

16. Lung Cancer Therapeutics Market, by Region

  • 16.1. Americas
    • 16.1.1. North America
    • 16.1.2. Latin America
  • 16.2. Europe, Middle East & Africa
    • 16.2.1. Europe
    • 16.2.2. Middle East
    • 16.2.3. Africa
  • 16.3. Asia-Pacific

17. Lung Cancer Therapeutics Market, by Group

  • 17.1. ASEAN
  • 17.2. GCC
  • 17.3. European Union
  • 17.4. BRICS
  • 17.5. G7
  • 17.6. NATO

18. Lung Cancer Therapeutics Market, by Country

  • 18.1. United States
  • 18.2. Canada
  • 18.3. Mexico
  • 18.4. Brazil
  • 18.5. United Kingdom
  • 18.6. Germany
  • 18.7. France
  • 18.8. Russia
  • 18.9. Italy
  • 18.10. Spain
  • 18.11. China
  • 18.12. India
  • 18.13. Japan
  • 18.14. Australia
  • 18.15. South Korea

19. United States Lung Cancer Therapeutics Market

20. China Lung Cancer Therapeutics Market

21. Competitive Landscape

  • 21.1. Market Concentration Analysis, 2024
    • 21.1.1. Concentration Ratio (CR)
    • 21.1.2. Herfindahl Hirschman Index (HHI)
  • 21.2. Recent Developments & Impact Analysis, 2024
  • 21.3. Product Portfolio Analysis, 2024
  • 21.4. Benchmarking Analysis, 2024
  • 21.5. AbbVie Inc.
  • 21.6. Amgen Inc.
  • 21.7. Astellas Pharma Inc.
  • 21.8. AstraZeneca PLC
  • 21.9. Bayer AG
  • 21.10. Boehringer Ingelheim International GmbH
  • 21.11. Johnson & Johnson Services, Inc.
  • 21.12. Merck & Co., Inc.
  • 21.13. Novartis AG
  • 21.14. Pfizer Inc.
  • 21.15. Sanofi S.A
  • 21.16. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL LUNG CANCER THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 3. GLOBAL LUNG CANCER THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 4. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PRESCRIPTION STATUS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 16. CHINA LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PLATINUM-BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PLATINUM-BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PLATINUM-BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TAXANES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TAXANES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TAXANES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRACHYTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRACHYTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRACHYTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EXTERNAL BEAM RADIATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EXTERNAL BEAM RADIATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EXTERNAL BEAM RADIATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STEREOTACTIC BODY RADIATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STEREOTACTIC BODY RADIATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STEREOTACTIC BODY RADIATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ANTIEMETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ANTIEMETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ANTIEMETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BONE-MODIFYING AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BONE-MODIFYING AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BONE-MODIFYING AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HEMATOPOIETIC GROWTH FACTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HEMATOPOIETIC GROWTH FACTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HEMATOPOIETIC GROWTH FACTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRAF INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRAF INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRAF INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST-LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST-LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST-LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND-LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND-LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND-LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD-LINE & BEYOND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD-LINE & BEYOND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD-LINE & BEYOND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE I, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE I, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE I, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE III, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE III, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE III, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE IV, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE IV, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STAGE IV, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRANDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GENERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY OFFLINE RETAIL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY OFFLINE RETAIL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY OFFLINE RETAIL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ONLINE RETAIL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ONLINE RETAIL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ONLINE RETAIL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ADENOCARCINOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ADENOCARCINOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ADENOCARCINOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LARGE CELL CARCINOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LARGE CELL CARCINOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LARGE CELL CARCINOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SQUAMOUS CELL CARCINOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SQUAMOUS CELL CARCINOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SQUAMOUS CELL CARCINOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SMALL CELL LUNG CANCER (SCLC), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SMALL CELL LUNG CANCER (SCLC), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SMALL CELL LUNG CANCER (SCLC), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY AMBULATORY INFUSION CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY AMBULATORY INFUSION CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY AMBULATORY INFUSION CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 153. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 155. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 156. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 157. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 158. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 159. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 160. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 161. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 162. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 163. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), 2018-2032 (USD MILLION)
  • TABLE 166. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 170. NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 172. NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 174. NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 176. NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 178. NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), 2018-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. LATIN AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 186. LATIN AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 188. LATIN AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 190. LATIN AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 192. LATIN AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 194. LATIN AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), 2018-2032 (USD MILLION)
  • TABLE 196. LATIN AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE LUNG CANCER THERAPEUTICS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 228. MIDDLE EAST LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 230. MIDDLE EAST LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 232. MIDDLE EAST LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 234. MIDDLE EAST LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 236. MIDDLE EAST LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST LUNG CANCER THERAPEUTICS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 238. MIDDLE EAST LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. MIDDLE EAST LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), 2018-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 243. AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 245. AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 246. AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 247. AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 248. AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 249. AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 250. AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 251. AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 252. AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 253. AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 254. AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), 2018-2032 (USD MILLION)
  • TABLE 256. AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 263. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 264. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 265. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 266. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 267. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 268. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 269. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), 2018-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 272. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 273. ASEAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 274. ASEAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. ASEAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 276. ASEAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 277. ASEAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 278. ASEAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 279. ASEAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 280. ASEAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 281. ASEAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 282. ASEAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 283. ASEAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 284. ASEAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 285. ASEAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 286. ASEAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), 2018-2032 (USD MILLION)
  • TABLE 287. ASEAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 288. GCC LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 289. GCC LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 290. GCC LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 291. GCC LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 292. GCC LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 293. GCC LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 294. GCC LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 295. GCC LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 296. GCC LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 297. GCC LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 298. GCC LUNG CANCER THERAPEUTICS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 299. GCC LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 300. GCC LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 301. GCC LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), 2018-2032 (USD MILLION)
  • TABLE 302. GCC LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 303. EUROPEAN UNION LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 304. EUROPEAN UNION LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 305. EUROPEAN UNION LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 306. EUROPEAN UNION